C12N 2795/00061
Methods of inactivation or attenuation
C12N2795/00061 (Methods of inactivation or attenuation) appears on 7 US grants and 14 published applications in this corpus.
Search patents in C12N- Granted patents
- 7
- Published applications
- 14
- Assignees
- 9
- Inventors
- 29
- Latest grant
- 22 Aug 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 0 |
| 2012 | 0 | 3 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 2 |
| 2019 | 0 | 0 |
| 2020 | 2 | 4 |
| 2021 | 0 | 0 |
| 2022 | 2 | 1 |
| 2023 | 2 | 0 |
By publication year.
Subgroups
Granted patents
Recent patents
- Mechanical method of maintaining narrow residence time distributions in continuous flow systems22 Aug 2023US 11,732,003 B2EMD Millipore Corporation
- Recombinant type I CRISPR-CAS system20 Jun 2023US 11,680,259 B2North Carolina State University
- Inactivation of viruses15 Mar 2022US 11,274,274 B2Global Life Sciences Solutions USA LLC
- Dual anthrax-plague vaccines that can protect against two tier-1 bioterror pathogens, bacillus anthracis and yersinia pestis11 Jan 2022US 11,219,686 B2The Catholic University of America
- Recombinant type I CRISPR-Cas system14 Jul 2020US 10,711,267 B2North Carolina State University
- Genetically Engineered Bacteriophage3 Nov 2022US 2022/0348886 A1Cytophage Technologies Inc.
- Recombinant type i crispr-cas system10 Dec 2020US 2020/0385702 A1North Carolina State University
- Mechanical Method Of Maintaining Narrow Residence Time Distributions In Continuous Flow Systems4 Jun 2020US 2020/0172568 A1EMD Millipore Corporation
- Dual anthrax-plague vaccines that can protect against two tier-1 bioterror pathogens, bacillus anthracis and yersinia pestis14 May 2020US 2020/0147207 A1The Catholic University of America
- Recombinant type i crispr-cas system2 Apr 2020US 2020/0102551 A1North Carolina State University
Most cited
By later US patents
- Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer8US 8,507,445 B2Board of Regents, The University of Texas System · 2013
- Recombinant type I CRISPR-Cas system4US 10,711,267 B2North Carolina State University · 2020
- Recombinant type I CRISPR-CAS system3US 11,680,259 B2North Carolina State University · 2023